Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Rheumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy

NCT01034137 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01034137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01034137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Rheumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
September 30, 2014
Enrollment
317 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis